OTCMKTS:RHHBY - Roche Holdings AG Basel Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$30.95 -0.03 (-0.10 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$30.98
Today's Range$30.95 - $31.22
52-Week Range$26.30 - $32.42
Volume1.13 million shs
Average Volume1.53 million shs
Market Capitalization$214.00 billion
P/E Ratio15.87
Dividend Yield2.84%
Beta0.53
Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories; and collaboration agreements with Five Prime Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and SQZ Biotechnologies Company. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RHHBY
Previous Symbol
CUSIPN/A
Phone41-61-688-1111

Debt

Debt-to-Equity Ratio0.53
Current Ratio1.28
Quick Ratio0.97

Price-To-Earnings

Trailing P/E Ratio15.87
Forward P/E Ratio13.69
P/E Growth1.9

Sales & Book Value

Annual Sales$54.15 billion
Price / Sales3.90
Cash Flow$2.5101 per share
Price / Cash12.33
Book Value$4.33 per share
Price / Book7.15

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees93,734
Outstanding Shares6,815,420,000
Market Cap$214.00 billion
OptionableNot Optionable

Roche Holdings AG Basel (OTCMKTS:RHHBY) Frequently Asked Questions

What is Roche Holdings AG Basel's stock symbol?

Roche Holdings AG Basel trades on the OTCMKTS under the ticker symbol "RHHBY."

What price target have analysts set for RHHBY?

10 equities research analysts have issued 1-year target prices for Roche Holdings AG Basel's shares. Their forecasts range from $34.00 to $34.00. On average, they expect Roche Holdings AG Basel's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for Roche Holdings AG Basel.

What is the consensus analysts' recommendation for Roche Holdings AG Basel?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche Holdings AG Basel in the last year. There are currently 3 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Roche Holdings AG Basel.

Has Roche Holdings AG Basel been receiving favorable news coverage?

Press coverage about RHHBY stock has been trending somewhat negative on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Roche Holdings AG Basel earned a news impact score of -1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of Roche Holdings AG Basel's key competitors?

Who are Roche Holdings AG Basel's key executives?

Roche Holdings AG Basel's management team includes the folowing people:
  • Dr. Severin Schwan, CEO & Exec. Director (Age 51)
  • Ms. Cristina A. Wilbur, Head of Group HR (Age 51)
  • Dr. Alan Hippe, Chief Financial & Information Officer (Age 51)
  • Dr. Karl Mahler, Head of Investor Relations
  • Dr. Gottlieb A. Keller, Gen. Counsel & Corp. Sec. (Age 64)

Who are Roche Holdings AG Basel's major shareholders?

Roche Holdings AG Basel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bristol John W & Co. Inc. NY (0.02%), Douglass Winthrop Advisors LLC (0.01%), Riverbridge Partners LLC (0.01%), Boston Common Asset Management LLC (0.01%), Ferguson Wellman Capital Management Inc. (0.00%) and Osher Van de Voorde Investment Management (0.00%).

Which major investors are selling Roche Holdings AG Basel stock?

RHHBY stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Douglass Winthrop Advisors LLC, Kidder Stephen W, Hemenway Trust Co LLC, Somerville Kurt F, Bristol John W & Co. Inc. NY, Broderick Brian C and Scout Investments Inc..

Which major investors are buying Roche Holdings AG Basel stock?

RHHBY stock was purchased by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC, Patten Group Inc., Gardiner Nancy B, Pacer Advisors Inc., Advisor Partners LLC, Ferguson Wellman Capital Management Inc., Dearborn Partners LLC and Cornerstone Investment Partners LLC.

How do I buy shares of Roche Holdings AG Basel?

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roche Holdings AG Basel's stock price today?

One share of RHHBY stock can currently be purchased for approximately $30.95.

How big of a company is Roche Holdings AG Basel?

Roche Holdings AG Basel has a market capitalization of $214.00 billion and generates $54.15 billion in revenue each year. The company earns $8.77 billion in net income (profit) each year or $1.95 on an earnings per share basis. Roche Holdings AG Basel employs 93,734 workers across the globe.

What is Roche Holdings AG Basel's official website?

The official website for Roche Holdings AG Basel is http://www.roche.com.

How can I contact Roche Holdings AG Basel?

Roche Holdings AG Basel's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]


MarketBeat Community Rating for Roche Holdings AG Basel (OTCMKTS RHHBY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Roche Holdings AG Basel and other stocks. Vote "Outperform" if you believe RHHBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RHHBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel